1 tivity to the therapeutic anticholinesterase metrifonate.

2                            Bath perfusion of metrifonate (10-200 microM) dose-dependently decreased b

3 trifonate ex vivo, because bath perfusion of metrifonate (50 microM) significantly decreased the AHP

4                               The effects of metrifonate, a second generation cholinesterase inhibito

5 commodation in neurons from both chronically metrifonate- and vehicle-treated aging rabbits.

6 s that can plague ChE inhibitors, supporting metrifonate as a possible treatment for the cognitive de

7 tment did not result in a desensitization to metrifonate ex vivo, because bath perfusion of metrifona

8 reatment with the long-lasting ChE inhibitor metrifonate facilitated acquisition and retention of eye

9  from aging rabbits chronically treated with metrifonate had significantly reduced spike frequency ac

10 ed from mice treated with sublethal doses of metrifonate, has demonstrated that enzyme modifications

11                       The effects of chronic metrifonate treatment (12 mg/kg for 3 weeks) on CA1 neur

12                                      Chronic metrifonate treatment did not result in a desensitizatio

13 pose that the facilitating effect of chronic metrifonate treatment on acquisition of hippocampus-depe

14                                              Metrifonate treatment resulted in steady-state, dose-dep

15                                              Metrifonate was behaviorally effective in the absence of

16 rase inhibitors rivastigmine, donepezil, and metrifonate, which are devoid of nicotinic APL action, d